Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DSP-0390 in recurrent high-grade glioma
jRCT2031210299Phase 1Suspended
- Sponsor
- Sumitomo Pharma
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of DSP-0390 in glioma (2 arms), sponsored by Sumitomo Pharma. Primary endpoints: Safety and tolerability, Maximum tolerated dose and/or recommended dose for expansion and 2 more. Started Sep 2021; status: suspended.
02
Drugs
DSP-0390
03
Conditions
glioma
Beyond the preview
Go deeper on jRCT2031210299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210299.